Potent candidates for Targeted Alpha Therapy (TAT)
Filosofov D. Baimukhanova A. Khushvaktov J. Kurakina E. Radchenko V.
1 July 2025Elsevier Inc.
Nuclear Medicine and Biology
2025#146-147
Targeted Alpha Therapy (TAT) holds significant promise as a localized treatment for cancer. Encouraging clinical results from using peptides and antibodies labeled with alpha emitters to treat patients with metastatic cancers, particularly those who have not responded to other therapies, provide compelling evidence of TATs potential. To fully realize the benefits of TAT, it is essential to carefully select appropriate radionuclides and targeting delivery systems to maximize therapeutic efficacy while minimizing nonspecific toxicity to healthy tissues. This review explores key radiochemical, radiopharmaceutical, and radiation-biological considerations for current TAT candidates, and proposes additional potential candidates, establishing a foundation and criteria for the ongoing development of TAT radiopharmaceuticals.
Alpha emitters , Dosimetry , Production , Research candidates , Targeted alpha radionuclide therapy (TAT)
Text of the article Перейти на текст статьи
Laboratory of Nuclear Problems, Joint Institute for Nuclear Research, Joliot-Curie St. 6, Dubna, 141980, Russian Federation
Scientific and Technical Center of Radiochemistry and Isotopes Production, Institute of Nuclear Physics, Ibragimov St. 1, Almaty, 050032, Kazakhstan
Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, V6T 1Z1, BC, Canada
Laboratory of Nuclear Problems
Scientific and Technical Center of Radiochemistry and Isotopes Production
Department of Chemistry
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026